Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose IV AZD0292 in healthy Japanese participants
jRCT2071250102Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD-0292 in bronchiectasis, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability, Safety laboratory parameters and 2 more. Started Dec 2025; status: completed.
02
Drugs
AZD-0292
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on jRCT2071250102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250102.